Research programme: phosphodiesterase IV inhibitors - Celltech/Merck
Alternative Names: PDE4 inhibitors research programme - Celltech/MerckLatest Information Update: 21 Sep 2007
At a glance
- Originator Celltech Group
- Developer Celltech Group; Merck & Co
- Class
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 29 Sep 2003 Merck & Co. has extended the development period of its phosphodiesterase-IV inhibitors collaboration with Celltech Group
- 25 Apr 2003 Preclinical trials in Asthma (PO)
- 25 Apr 2003 Preclinical trials in Chronic obstructive pulmonary disease (PO)